Alzheimer’s Disease Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Alzheimer’s Disease pipeline constitutes 110+ key companies continuously working towards developing 120+ Alzheimer’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Alzheimer’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Alzheimer’s Disease Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer’s Disease Market.


Some of the key takeaways from the Alzheimer’s Disease Pipeline Report: 

Companies across the globe are diligently working toward developing novel Alzheimer’s Disease treatment therapies with a considerable amount of success over the years. 

Alzheimer’s Disease companies working in the treatment market are Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others, are developing therapies for the Alzheimer’s Disease treatment 

Emerging Alzheimer’s Disease therapies in the different phases of clinical trials are- NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others are expected to have a significant impact on the Alzheimer’s Disease market in the coming years.   

In March 2024, MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted novel treatments for debilitating CNS disorders, announced the start of a Phase 1 clinical trial for ML-007/PAC. This is an extended-release fixed-dose combination of the novel investigational muscarinic agonist ML-007 and a precision-matched peripherally active anticholinergic (PAC). The trial builds on findings from three previous Phase 1 trials that assessed the safety and tolerability of ML-007 with PAC. The data from this new trial will guide the dosing regimen for upcoming Phase 2 trials targeting schizophrenia and Alzheimer’s disease psychosis. The company plans to start its first Phase 2 trial of ML-007/PAC in schizophrenia later this year.

In January 2024, AmyriAD Therapeutics plans to assess its leading Alzheimer’s disease small molecule candidate, AD-101, in three forthcoming Phase III studies.

In July 2023, Following a conclusion that a confirmatory trial demonstrated clinical benefit, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), intended to treat adult patients with Alzheimer’s Disease, to conventional approval. Leqembi is the first amyloid beta-directed antibody for the treatment of Alzheimer’s disease to transition from an accelerated approval to a conventional approval.


Alzheimer’s Disease Overview

Alzheimer’s disease is a progressive neurodegenerative disorder that primarily affects older adults, leading to cognitive decline, memory loss, and changes in behavior and personality. It is the most common cause of dementia, accounting for 60-80% of dementia cases.


Get a Free Sample PDF Report to know more about Alzheimer’s Disease Pipeline Therapeutic Assessment-


Emerging Alzheimer’s Disease Drugs Under Different Phases of Clinical Development Include:

NRDN-201: Neurodon

ST-501: Sangamo Therapeutics

SNK 01: NKGen Biotech

ASN51: Asceneuron

TB 006: TrueBinding

AL002: Alector

CT-1812: Cognition Therapeutics

Blarcamesine: Anavex Life Sciences

E 2814: Eisai Co Ltd

Simufilam: Cassava Sciences, Inc.

KarXT: Karuna Therapeutics

NE3107: BioVie


Alzheimer’s Disease Route of Administration

Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 







Alzheimer’s Disease Molecule Type

Alzheimer’s Disease Products have been categorized under various Molecule types, such as

Monoclonal Antibody



Small molecule

Gene therapy 


Alzheimer’s Disease Pipeline Therapeutics Assessment

Alzheimer’s Disease Assessment by Product Type

Alzheimer’s Disease By Stage and Product Type

Alzheimer’s Disease Assessment by Route of Administration

Alzheimer’s Disease By Stage and Route of Administration

Alzheimer’s Disease Assessment by Molecule Type

Alzheimer’s Disease by Stage and Molecule Type


DelveInsight’s Alzheimer’s Disease Report covers around 120+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration


Further Alzheimer’s Disease product details are provided in the report. Download the Alzheimer’s Disease pipeline report to learn more about the emerging Alzheimer’s Disease therapies


Some of the key companies in the Alzheimer’s Disease Therapeutics Market include:

Key companies developing therapies for Alzheimer’s Disease are – AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc., and others.


Alzheimer’s Disease Pipeline Analysis:

The Alzheimer’s Disease pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer’s Disease with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s Disease Treatment.

Alzheimer’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Alzheimer’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Alzheimer’s Disease drugs and therapies


Alzheimer’s Disease Pipeline Market Drivers

Increase in prevalence of Alzheimer’s Disease (AD), rising geriatric population are some of the important factors that are fueling the Alzheimer’s Disease Market.


Alzheimer’s Disease Pipeline Market Barriers

However, clinical trials are more complicated, costly, and slower than trials for other diseases., lack of clear diagnosis and other factors are creating obstacles in the Alzheimer’s Disease Market growth.


Scope of Alzheimer’s Disease Pipeline Drug Insight    

Coverage: Global

Key Alzheimer’s Disease Companies: Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others

Key Alzheimer’s Disease Therapies: NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others

Alzheimer’s Disease Therapeutic Assessment: Alzheimer’s Disease current marketed and Alzheimer’s Disease emerging therapies

Alzheimer’s Disease Market Dynamics: Alzheimer’s Disease market drivers and Alzheimer’s Disease market barriers 


Request for Sample PDF Report for Alzheimer’s Disease Pipeline Assessment and clinical trials


Table of Contents 

1. Alzheimer’s Disease Report Introduction

2. Alzheimer’s Disease Executive Summary

3. Alzheimer’s Disease Overview

4. Alzheimer’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Alzheimer’s Disease Pipeline Therapeutics

6. Alzheimer’s Disease Late Stage Products (Phase II/III)

7. Alzheimer’s Disease Mid Stage Products (Phase II)

8. Alzheimer’s Disease Early Stage Products (Phase I)

9. Alzheimer’s Disease Preclinical Stage Products

10. Alzheimer’s Disease Therapeutics Assessment

11. Alzheimer’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Alzheimer’s Disease Key Companies

14. Alzheimer’s Disease Key Products

15. Alzheimer’s Disease Unmet Needs

16 . Alzheimer’s Disease Market Drivers and Barriers

17. Alzheimer’s Disease Future Perspectives and Conclusion

18. Alzheimer’s Disease Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart